RX 0301
Alternative Names: HC-0301; RX-0301; WGI-0301Latest Information Update: 18 Sep 2025
At a glance
- Originator Rexahn Pharmaceuticals
 - Developer Rexahn Pharmaceuticals; Zhejiang Haichang Biotechnology
 - Class Antineoplastics; Antisense oligonucleotides
 - Mechanism of Action Proto-oncogene protein c-akt inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 - Available For Licensing Yes
 
Highest Development Phases
- Phase I Solid tumours
 - Preclinical Liver cancer
 - Discontinued Ovarian cancer; Pancreatic cancer; Renal cell carcinoma
 
Most Recent Events
- 18 Sep 2025 RX 0301 is still in phase-I clinical trials in Solid tumours(Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT05267899)
 - 22 Oct 2024 Ocuphire Pharma has merged with Opus Genetics to form Opus Genetics
 - 05 Apr 2024 Preclinical trials in Liver cancer in China (unspecified route) prior to April 2024